Neil Averitt commentary: AbbVie teaches remedies should focus on individual wrongdoers
In its recent challenge to bad-faith litigation by the AbbVie pharmaceutical corporation, the Federal Trade Commission set out an important and welcome marker on the merits, but it missed an opportunity...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content